Multi-Target Drugs for Kidney Diseases.

Abstract

Kidney diseases such as AKI, CKD, and GN can lead to dialysis and the need for kidney transplantation. The pathologies for kidney diseases are extremely complex, progress at different rates, and involve several cell types and cell signaling pathways. Complex kidney diseases require therapeutics that can act on multiple targets. In the past 10 years, in silico design of drugs has allowed for multi-target drugs to progress quickly from concept to reality. Several multi-target drugs have been made successfully to target AA pathways and transcription factors for the treatment of inflammatory, fibrotic, and metabolic diseases. Multi-target drugs have also demonstrated great potential to treat diabetic nephropathy and fibrotic kidney disease. These drugs act by decreasing renal TGF-β signaling, inflammation, mitochondrial dysfunction, and oxidative stress. There are several other recently developed multi-target drugs that have yet to be tested for their ability to combat kidney diseases. Overall, there is excellent potential for multi-target drugs that act on several cell types and signaling pathways to treat kidney diseases.

• Authors: John D Imig, Daniel Merk, Eugen Proschak
• Journal: Kidney360 (Kidney360) Vol. 2 Issue 10 Pg. 1645-1653 (10 28 2021) ISSN: 2641-7650 [Electronic] United States
• PMID: 35372984 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
• Copyright: Copyright © 2021 by the American Society of Nephrology.

Topics

• Humans
• Kidney (metabolism)
• Kidney Diseases (drug therapy)
• Kidney Transplantation
• Metabolic Diseases (metabolism)
• Renal Dialysis